Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Sees Large Decline in Short Interest

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 6,364 shares, a drop of 47.9% from the August 31st total of 12,218 shares. Based on an average daily volume of 2 shares, the short-interest ratio is presently 3,182.0 days.

Laboratorios Farmaceuticos Rovi Stock Performance

OTCMKTS:LABFF remained flat at C$67.17 during trading on Thursday. Laboratorios Farmaceuticos Rovi has a 1-year low of C$65.86 and a 1-year high of C$67.17. The business’s fifty day moving average is C$66.83 and its two-hundred day moving average is C$66.16.

About Laboratorios Farmaceuticos Rovi

Laboratorios Farmacéuticos Rovi, SA is a Spain-based pharmaceutical company engaged in the research, development, manufacture and commercialization of prescription medicines and other healthcare products. The company focuses on specialty pharmaceuticals, with activities spanning proprietary drug development, marketing and pharmaceutical manufacturing services.

Rovi’s portfolio includes medicines for areas such as thrombosis and other hospital and specialist-care indications. Its products include bemiparin, marketed under the Hibor brand in various markets, as well as long-acting injectable treatments developed using its ISM drug-delivery technology, including products based on risperidone.

In addition to its own branded products, Rovi operates as a contract development and manufacturing organization, providing pharmaceutical manufacturing services, particularly for injectable medicines.